FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103161844> ?p ?o ?g. }

• W2103161844 abstract "Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation caused by bronchial alterations, small airways disease and parenchymal destruction. In patients with COPD the structural and functional lung alterations can progress more or less rapidly from the initial small airways disease to an overt COPD where a severe expiratory flow limitation takes place. In these conditions, lung hyperinflation develops characterized by increase in functional residual capacity (FRC) and decrease in inspiratory capacity (IC). Thus, IC is an easy and reliable index to monitor lung hyperinflation and to assess the efficacy of bronchodilator drugs. When FRC increases, tidal volume (VT) is located in a more flatted upper part of the P -V curve of the respiratory system and respiratory muscles must sustain a greater elastic workload. Furthermore, due to inadequate time for expiration, there is a positive alveolar pressure at the end of expiration (PEEPi). This represents a further elastic workload for the inspiratory muscles. This impairment of ventilatory mechanics generates dyspnea that in most severely compromised patients occurs also for small efforts causing activity limitation and worst health-related quality of life (HRQoL). Due to these respiratory alterations, bronchodilators are the cornerstone of the long-term treatment of COPD in order to decrease airways resistances, lung hyperinflation and exacerbation rate, and improve patient's symptoms, exercise tolerance and health status. Long-acting antimuscarinic bronchodilators (LAMAs) have proven to be very useful in terms of lung deflation and exercise tolerance. Recently, new LAMAs with several positive characteristics have been introduced into clinical use among which glycopyrronium bromide has shown to be particularly effective. Glycopyrronium has a longer-lasting effect compared to other anticholinergic drugs, therefore it allows a single daily administration and facilitates the therapy of a disease that needs a chronic bronchodilation by decreasing the mechanic stress of the airways determined by repeated bronchoconstriction and increasing patient's adherence to treatment plan with better clinical results. Several studies demonstrated that glycopyrronium is able to positively and significantly decrease lung hyperinflation, symptoms, and improve psycho-physical status of COPD patients, with a low rate of adverse events, similar to that of placebo." @default.
• W2103161844 created "2016-06-24" @default.
• W2103161844 creator A5044945392 @default.
• W2103161844 date "2014-04-01" @default.
• W2103161844 modified "2023-09-26" @default.
• W2103161844 title "The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients" @default.
• W2103161844 cites W105787228 @default.
• W2103161844 cites W1858482906 @default.
• W2103161844 cites W1862464476 @default.
• W2103161844 cites W1922511748 @default.
• W2103161844 cites W1979808988 @default.
• W2103161844 cites W1984207232 @default.
• W2103161844 cites W1985644458 @default.
• W2103161844 cites W1989738601 @default.
• W2103161844 cites W2000430593 @default.
• W2103161844 cites W2001097201 @default.
• W2103161844 cites W2003170276 @default.
• W2103161844 cites W2009498514 @default.
• W2103161844 cites W2017287154 @default.
• W2103161844 cites W2019464077 @default.
• W2103161844 cites W2024631328 @default.
• W2103161844 cites W2026922655 @default.
• W2103161844 cites W2048251717 @default.
• W2103161844 cites W2051659559 @default.
• W2103161844 cites W2070015120 @default.
• W2103161844 cites W2072228223 @default.
• W2103161844 cites W2088022718 @default.
• W2103161844 cites W2095049468 @default.
• W2103161844 cites W2095666112 @default.
• W2103161844 cites W2096467996 @default.
• W2103161844 cites W2102060580 @default.
• W2103161844 cites W2104015319 @default.
• W2103161844 cites W2108642838 @default.
• W2103161844 cites W2109662587 @default.
• W2103161844 cites W2111861387 @default.
• W2103161844 cites W2117250400 @default.
• W2103161844 cites W2121197634 @default.
• W2103161844 cites W2121914298 @default.
• W2103161844 cites W2125373114 @default.
• W2103161844 cites W2127159607 @default.
• W2103161844 cites W2128613750 @default.
• W2103161844 cites W2133399653 @default.
• W2103161844 cites W2134091333 @default.
• W2103161844 cites W2136581092 @default.
• W2103161844 cites W2138305742 @default.
• W2103161844 cites W2138833643 @default.
• W2103161844 cites W2140200862 @default.
• W2103161844 cites W2141034778 @default.
• W2103161844 cites W2144702378 @default.
• W2103161844 cites W2145466675 @default.
• W2103161844 cites W2149199480 @default.
• W2103161844 cites W2150990823 @default.
• W2103161844 cites W2155395559 @default.
• W2103161844 cites W2157195372 @default.
• W2103161844 cites W2157243339 @default.
• W2103161844 cites W2160609432 @default.
• W2103161844 cites W2160693139 @default.
• W2103161844 cites W2163967221 @default.
• W2103161844 cites W2167652046 @default.
• W2103161844 cites W2167941825 @default.
• W2103161844 cites W2171974515 @default.
• W2103161844 cites W2173621900 @default.
• W2103161844 cites W2180474633 @default.
• W2103161844 cites W2319554819 @default.
• W2103161844 cites W2326270375 @default.
• W2103161844 cites W4213189266 @default.
• W2103161844 doi "https://doi.org/10.1186/2049-6958-9-19" @default.
• W2103161844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4229742" @default.
• W2103161844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24690294" @default.
• W2103161844 hasPublicationYear "2014" @default.
• W2103161844 type Work @default.
• W2103161844 sameAs 2103161844 @default.
• W2103161844 citedByCount "6" @default.
• W2103161844 countsByYear W21031618442017 @default.
• W2103161844 countsByYear W21031618442018 @default.
• W2103161844 countsByYear W21031618442020 @default.
• W2103161844 countsByYear W21031618442022 @default.
• W2103161844 crossrefType "journal-article" @default.
• W2103161844 hasAuthorship W2103161844A5044945392 @default.
• W2103161844 hasBestOaLocation W21031618441 @default.
• W2103161844 hasConcept C126285488 @default.
• W2103161844 hasConcept C126322002 @default.
• W2103161844 hasConcept C162324750 @default.
• W2103161844 hasConcept C163498912 @default.
• W2103161844 hasConcept C164705383 @default.
• W2103161844 hasConcept C27101514 @default.
• W2103161844 hasConcept C2776042228 @default.
• W2103161844 hasConcept C2776164194 @default.
• W2103161844 hasConcept C2776780178 @default.
• W2103161844 hasConcept C2777714996 @default.
• W2103161844 hasConcept C2779975672 @default.
• W2103161844 hasConcept C2781018748 @default.
• W2103161844 hasConcept C42219234 @default.
• W2103161844 hasConcept C534529494 @default.
• W2103161844 hasConcept C556758197 @default.
• W2103161844 hasConcept C56283660 @default.
• W2103161844 hasConcept C71924100 @default.
• W2103161844 hasConcept C91102366 @default.
• W2103161844 hasConceptScore W2103161844C126285488 @default.
• W2103161844 hasConceptScore W2103161844C126322002 @default.

• next